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INTRODUCTION
Tuberculosis still remains one of the leading causes of mor-
bidity and mortality worldwide. Controlling tuberculosis
becomes more difficult by the emergence of drug-resistant
Mycobacterium tuberculosis. The global surveillance program
reported that resistance to anti-tuberculous drugs was found
in all 35 countries and has become a global problem (1).
The overall prevalence was 12.6% for single drug resistance
(range, 2.3-42.4%) and 2.2% for multidrug resistance (range,
0-22.1%). Patients infected with drug-resistant M. tubercu-
losis strains are less likely to be cured, particularly if they are
suffering from recurrent infections, malnourished, or infect-
ed with human immunodeficiency virus (HIV) (2). Second-
line antituberculous drugs for patients infected with drug
resistant M. tuberculosis are usually not bactericidal and more
expensive (3).
According to a Korean national survey of 2,486 M. tuber-
culosis strains isolated from patients without prior treatment,
282 (11.3%) isolates exhibited resistance to one or more
drugs (4). Among the 282 drug resistant strains, 19 (6.7%)
were resistant to pyrazinamide (PZA). Interestingly, all PZA
resistant strains showed resistance to other first-line drugs
such as isoniazid, rifampin, and ethambutol. With this back-
ground, an accurate and rapid method to determine PZA
susceptibility is crucial for the successful treatment of mul-
tidrug resistant tuberculosis in Korea.
PZA is a prodrug that is converted to bactericidal pyrazi-
noic acid by pyrazinamidase (PZase) produced by M. tuber-
culosis. Functioning exclusively in the acid environment (pH
5.0-5.5) at the site of bacterial infection (5), PZA can kill
semi-dormant (6) and probably intracellular M. tuberculosis
(7). This characteristic of PZA makes it possible to reduce
total duration of treatment from 12-18 months to 6 months
(8, 9). 
PZA susceptibility is usually determined by growth of
M. tuberculosis on a medium containing PZA by measuring
the minimum inhibitory concentration (MIC) (10). Alter-
natively, PZA susceptibility has also been determined by
detecting PZase activity of the cultured M. tuberculosis (11,
12) as PZase activity is lost in PZA-resistant isolates (13).
However, these conventional culture-based methods require
up to 3 months and exhibit high discordance rates among
laboratories (14). A major source of discordance seems to
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Characterization of pncA Mutations of Pyrazinamide-Resistant
Mycobacterium tuberculosis in Korea
Pyrazinamide (PZA) is one of the most important drugs for the treatment of
Mycobacterium tuberculosis infection. However, the increasing frequency of
PZA-resistant strains limits its effectiveness. In Korea, most PZA-resistant
strains also exhibit both isoniazid and rifampin resistance making it essential to
identify these resistant strains accurately and rapidly for effective treatment of
mycobacterial infection. In this study, the characteristics and frequency of muta-
tions of the pncA gene encoding pyrazinamidase were investigated in PZA-
resistant clinical isolates from Korea. Automated DNA sequencing was used to
evaluate the usefulness of DNA-based detection of PZA resistance. Among 95
PZA-resistant clinical isolates, 92 (97%) exhibited mutations potentially affecting
either the production or the activity of the enzyme. Mutations were found
throughout the pncA gene including the upstream region. Single nucleotide
replacement appeared to be the major mutational event (69/92), although multi-
ple substitutions as well as insertion and deletion of nucleotides were also iden-
tified. The high frequency of pncA mutations observed in this study supports the
usefulness of DNA-based detection of PZA-resistant M. tuberculosis. Having
verified the scattered and diverse mutational characteristics of the pncA gene,
automated DNA sequencing seems to be the best strategy for rapid detection of
PZA-resistant M. tuberculosis.
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originate from the low pH environment of the medium
that is required for conversion of PZA to pyrazinoic acid,
but is undesirable for growth of M. tuberculosis (15). 
In 1996, the gene in M. tuberculosis encoding PZase, pncA,
was characterized (16). The gene consists of 561 bp encoding
a 20 kDa enzyme with 186 amino acids. Mutation of the
pncA gene was suggested as the major mechanism of PZA
resistance. Several subsequent studies including 20-40 PZA-
resistant M. tuberculosis isolates from different countries con-
firmed the close correlation between pncA mutation and PZA
resistance (72-97%) (17-23). These observations raised the
possibility of utilizing DNA-based methods as an alterna-
tive PZA susceptibility test. 
Since M. tuberculosis isolates from each country exhibit a
unique DNA- fingerprint (24), it is possible that the genetic
factors controlling resistance may vary. In addition, recent
reports have suggested that mutations in the pncA gene could
be specific to subtypes of M. tuberculosis (23) and/or to the
geographic source of the isolate (17). In this study, the pncA
gene sequence was characterized in 95 multidrug resistant,
PZase negative M. tuberculosis strains isolated from Korean
patients to define any possible geographic preferences for
mutations in the gene, and to evaluate the utility of a DNA-
based detection test for PZA-resistant M. tuberculosis isolates
in Korea. 
MATERIALS AND METHODS
Bacterial strains
Two strains of M. tuberculosis, H37Rv (ATCC 27294) and
M. tuberculosis (ATCC 35806), were included as PZA-sus-
ceptible controls. Ninety-five PZA-resistant M. tuberculosis
isolates from sputum cultures grown on Ogawa medium
were obtained from the Korean Institute of Tuberculosis,
which participated in the WHO-IUATLD global project
(1). Resistance to PZA was determined by the PZase test
using the Wayne method (25). All PZA-resistant strains
showed concomitant resistance to isoniazid, rifampin, and
ethambutol.
pncA gene amplification
Bacterial DNA was extracted using a kit according to the
manufacturer’ s instructions (DNA PrepMate-M, Bioneer
Corp, Cheongwon, Korea). The pncA gene was amplified
from each M. tuberculosis isolate using primers, P1 and P6,
as previously described by Scorpio et al. (22). These primers
anneal -105 bp upstream of the start codon and 55 bp down-
stream of the stop codon of the pncA gene, respectively. The
expected size of the PCR product was 720 bp, which includ-
ed the full length of the pncA gene (561 bp). An additional
PCR primer set, P0 (annealing -177 bp upstream of the
pncA gene) and P2 (annealing at nucleotide positions 91 to
110 bp of the pncA gene), was used for several selected iso-
lates to study a larger segment of the upstream region in the
gene. The size of the PCR product using this second PCR
primer set was 287 bp in length.
PCR amplifications were carried out in a GeneAmp PCR
system 9600 thermocycler (Perkin-Elmer Corp., Foster City,
CA, U.S.A.). Reaction mixtures (100  L) contained 0.1-0.5
g bacterial DNA, 50 pmol of each PCR primer, 200  mol
of each deoxynucleotide (dATP, dCTP, dGTP, dTTP), 2.5
units Taq DNA polymerase (Bioline, London, U.K.), 15 mM
ammonium sulfate, 50 mM Tris-HCl (pH 8.8), 50  M
EDTA, 1.5 mM MgCl2, 0.01% (w/v) gelatin, 10 mM beta-
mercaptoethanol, and 10% (v/v) DMSO. The reaction mix-
tures were subjected to 5 min at 96℃ followed by 35 cycles
of 20 sec at 96℃, 30 sec at 55℃, 60 sec at 72℃ and ter-
minated by an additional 10 min at 72℃. Successful gene
amplifications were confirmed by UV transillumination fol-
lowing electrophoresis on a 1% agarose gel stained with
ethidium bromide in 1×TAE buffer.
DNA sequencing analysis
PCR products from each M. tuberculosis strain were puri-
fied with the PCR purification kit (Qiagen Inc., Valencia,
CA, USA), according to the manufacturer’ s instructions.
The purified PCR product was subjected to a sequencing
reaction using a BigDye Terminator Cycle Sequencing Kit
with AmpliTaq DNA Polymerase, FS (PE-Applied Biosys-
tems, CA, U.S.A.) and primers. The PCR primers were used
in the sequencing reaction to obtain complete sequence infor-
mation from both strands of the gene. Reaction products
were analyzed on a 5% Long Ranger gel (FMC BioProducts,
Rockland, Maine, U.S.A.) using an ABI Prism 377 DNA
Sequencer (PE-Applied Biosystems). Sequences were ana-
lyzed using Sequence Navigator software (PE-Applied Biosys-
tems).
RESULTS 
The majority, 92 of the 95 M. tuberculosis clinical isolates
(97%), exhibited mutations in the pncA gene as compared
to the wild type (PZA sensitive) sequence (Table 1). These
included 73 variations at 71 dispersed sites throughout the
pncA gene (Fig. 1A). Thirteen variations were found in more
than two isolates and 44 mutations were newly identified in
this study. The size of the alteration varied from one to 80
bp, although most of the mutations involved only a single
nucleotide (81/92; 88%). In contrast, no mutations were
found in the two PZA-susceptible M. tuberculosis strains. The
three PZA-resistant isolates that did not contain any alter-
ations and the two PZA-susceptible strains, were subjected
to further sequence analysis of the upstream regulatory regionpncA Mutations in Mycobacterium tuberculosis 539
(up to -177), but no alterations from the wild type sequence
were found.
Mutations included nucleotide substitutions (72/92 iso-
lates), deletions (10/92), and insertions (10/92) of the pncA
gene (Table 2). Three different types of nucleotide substitu-
tions were observed. First, six isolates carried mutations at
-11 (A→G), the upstream region of the gene. This muta-
tion was the most frequent alteration observed in this study.
Secondly, six isolates created a stop codon by single nucleo-
tide substitutions at positions 28, 203, 309, 357, or 421,
presumably leading to premature termination of protein
synthesis (Table 1). The remaining 60 isolates exhibited
A→G (-11) None 6
G→T (3)
� Met→Ile (1) 1
T→G (11)
� Leu→Trp (4) 1
G→T (19) Val→Phe (7) 1
T→A (20)
� Val→Asp (7) 1
A→G (23)
� Asp→Gly (8) 1
T→G (26)
� Val→Gly (9) 1
T→C (26)
� Val→Ala (9) 1
C→T (28) Gln→stop (10) 1
A→C (29) Gln→Pro (10) 3
A→G (29) Gln→Arg (10) 1
A→C (29), T→G (295)
� Gln→Pro (10), Tyr→Asp (99) 1
A→C (35) Asp→Ala (12) 1
T→C (40) Cys→Arg (14) 1
G→A (41)
� Cys→Tyr (14) 1
GT→TC (68-69)
� Gly→Val (23) 1
CC→AA (74-75), C→G (77),  Ala→Glu (25), Ala→Gly (26), 
C→A (83)
� Ala→Asp (28) 1
T→G (134)
� Val→Gly (45) 1
C→A (137) Ala→Glu (46) 1
A→G (139) Thr→Ala (47) 1
A→C (146)
� Asp→Ala (49) 1
C→G (169) His→Asp (57) 1
T→C (172) Phe→Leu (58) 1
T→G (190)
� Tyr→Asp (64) 1
T→C (199) Ser→Pro (67) 1
T→C (202)
� Trp→Arg (68) 2
T→G (202)
� Trp→Gly (68) 1
G→A (203) Trp→stop (68) 2
G→C (203)
� Trp→Ser (68) 1
A→C (226) Thr→Pro (76) 2
C→T (227) Thr→Ile (76) 1
G→A (233)
� Gly→Asp (78) 1
T→G (254) Leu→Arg (85) 1
T→C (254) Leu→Pro (85) 1
A→C (286)
� Lys→Gln (96) 1
A→G (286) Lys→Glu (96) 3
T→C (307) Tyr→His (103) 2
A→C (308)
� Tyr→Ser (103) 2
C→G (309) Tyr→stop (103) 1
G→A (357)
� Trp→stop (119) 1
G→C (362) Arg→Pro (121) 1
A→C (403)
� Thr→Pro (135) 2
G→A (406)
� Asp→Asn (136) 2
G→T (406)
� Asp→Tyr (136) 1
A→C (410) His→Pro (137) 1
G→A (415) Val→Met (139) 3
C→T (421)
� Gln→stop (141) 1
A→C (422) Gln→Pro (141) 2
G→A (436)
� Ala→Thr (146) 1
T→G (464) Val→Gly (155) 1
T→G (476)
� Leu→Arg (159) 1
T→C (515) Leu→Pro (172) 1
G→T (538)
� Val→Phe (180) 1
G deletion (77)
� 1
80 nucleotides deletion (151-230)
� 1
A deletion (158)
� 1
C deletion (161)
� 1
TACAG deletion (307-311)
� 1
C deletion (341) 1
GG deletion (381-382)
� 1
ATGT deletion (386-389)
� 1
G deletion (406)
� 1
T deletion (452)
� 1
T insertion (287)
� 1
18 nucleotide insertion (368)
� 1
AG insertion (382)
� 1
GG insertion (391) 1
G insertion (392)
� 1
G insertion (414)
� 1
T insertion (465)
� 2
TGAC insertion (480)
� 1
C insertion (532)
� 1
No. of
isolates
Table 1. pncA mutations identified in PZA-resistant M. tuberculosis isolates* in Korea
Changes
Nucleotide substitution
(position
� )
Amino acid substitution
(residue)
No. of
isolates
Changes
Nucleotide substitution
(position
� )
Amino acid substitution
(residue)
*, All isolates lacked PZase activity and showed multiple resistance to isoniazid, rifampin, and ethambutol. 
� , Number of nucleotide position was
counted from the start codon (ATG) of pncA gene. Nucleotides in the 5′ -upstream region of the gene are indicated by minus numbers. 
� , Newly iden-
tified mutations in this study
Nucleotide substitution 72/92 (78%)
Upstream region (-11) 6/72 1 bp
Creates stop codon 6/72 1 bp
Amino acid substitution 60/72 1-4 bp
Nucleotide deletion* 10/92 (11%) 1-80 bp
Nucleotide insertion* 10/92 (11%) 1-18 bp
Type of mutation Frequency (%) Size of mutation
Table 2. Characteristics of pncA mutations in PZA-resistant
M. tuberculosis isolates in Korea
*Results of mutation cause a frame shift presumably resulting in either
an abnormal or a prematurely truncated polypeptide540 K.W. Lee, J.-M. Lee, K.-S. Jung
nucleotide substitutions resulting in amino acid replace-
ments. All alterations affecting the coding sequence appear
to alter the protein sequence or expression; none was syn-
onymous (silent). 
A unique mutation at position 169 (CAC→GAC), defined
originally in Mycobacterium bovis, was also identified in one
M. tuberculosis isolate (16). Three isolates carried substitu-
tions at more than two sites (Table 1). One isolate carried
nucleotide substitutions at positions 29 (A to C) and 295 (T
to G) resulting in amino acid changes Gln→Pro (residue
10) and Tyr→Asp (residue 99), respectively. The second
isolate carried two nucleotide substitutions at positions 68
(G to T) and 69 (T to C) resulting in a single amino acid
change Gly→Val at residue 23. The third isolate carried
four nucleotide substitutions at positions 74 (C to A), 75 (C
to A), 77 (C to G), and 83 (C to A) resulting in Ala→Glu
(residue 25), Ala→Gly (residue 26), and Ala→Asp (residue
28), respectively.
Nucleotide deletions were found in 10 isolates and ranged
from one to 80 bp (Table 1). In four isolates, more than two
nucleotides were deleted. Nucleotide insertions were also
found in 10 isolates and all of them occurred in the 3′ -half
of the gene. Nucleotide insertions ranged from one to 18 bp.
In four isolates, more than two nucleotides were inserted.
Deletion or insertion of nucleotides caused reading frame
shift presumably resulting in either an abnormal or a pre-
maturely truncated polypeptide.
DISCUSSION
The relationship between PZA resistance and mutation of
the pncA gene has been under study ever since the gene was
identified and characterized (16). More than 200 PZA-sus-
ceptible M. tuberculosis strains failed to show any mutations
of the gene including silent substitutions (18-20, 23). In
contrast, diverse mutations at various sites of the pncA gene
were identified in PZA-resistant strains and the frequencies
of mutation varied among studies (75-100%) (17-23). In
this study of Korean isolates, the frequency of pncA muta-
tion appeared to be very high (97%) in PZA-resistant M.
tuberculosis. This suggests that a DNA-based testing method
detecting mutation in the pncA gene would be very useful as
an alternative PZA susceptibility test in Korea. The method
would overcome several problems encountered in conven-
tional methods such as limitations in sensitivity, reliability,
and the time requirements of the assay.
The DNA-based method, however, would still fail to
detect some PZA-resistant isolates, for example, three PZA-
resistant isolates with defective PZase activity in this study
which did not exhibit any mutations in the pncA gene. These
M. tuberculosis isolates have been observed previously (17, 21).
In addition, PZA-resistant isolates retaining PZase activity,
which are expected to carry a normal pncA gene, have also
been reported (21, 26, 27). This implies that other mecha-
nisms are involved in PZA resistance. Recently, two alterna-
tive mechanisms have been proposed: active efflux of bacte-
ricidal pyrazinoic acid from the organism (28) and defects
in PZA uptake of the organism (29, 30). Defects in other
genes, such as those required for PZase expression, might
also be a source of PZA resistance. Based on reports described
thus far, the frequency of M. tuberculosis in this category seems
to be fairly low and the detection of these isolates should
rely on conventional culture methods until the exact mech-
anisms are defined. Thus, initial screening by DNA-based
method followed by conventional culture-based method for
any mutation negative isolates, might be appropriate.
Several characteristics of pncA gene mutation in M. tuber-
culosis can be pointed out based on the data obtained in this
and previously reported studies. First of all, the mutations
Fig. 1. Locations of pncA mutations found in PZA-resistant M. tuberculosis. Mutations in the 5′ -upstream region of the gene are indi-
cated as nucleotide position and labeled by minus numbers. Mutations in the coding region are labeled by positive codon numbers.
The gene is 186 codons in length. Mutations have been found from -12 (T→G) through the entire coding region of the gene (20). (A)
Location of alterations in 92 mutants identified in this study, (B) Location of alterations obtained from 254 previously reported mutants
(16-23, 26, 37) as well as from the 92 mutants in this study. 
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of the gene were too diverse to address any geographic pref-
erence. The 73 types of variation including 44 never observed
previously, were identified from 92 mutants in this study
(Table 1). Other studies also reported new variants. Second-
ly, the types of mutation are diverse: nucleotide substitu-
tions (78%), deletions (11%), and insertions (11%) have all
been observed. This characteristic was also observed in pre-
vious studies (19, 21-23). There appears to be a higher ten-
dency toward nucleotide deletion and insertion in the pncA
gene compared to mutations found in rpoB gene related to
rifampin-resistance (31). 
In addition, most of the mutations involved a single nu-
cleotide (81/92, 88%) and majority of them was nucleotide
substitution (69/81). Every mutation found thus far seems
to be detrimental to the function of the PZase since all iso-
lates were selected based on a defect in enzyme activity. This
implies that the function of the enzyme is very sensitive to
sequence alterations in any region of the polypeptide. In
general, single amino acid substitutions have been known to
be sufficient to eradicate or reduce stability of the enzyme
by changes in conformation and/or alteration of hydrogen
bonds or salt bridges of the polypeptide (32, 33). Interest-
ingly, 25% of the replacement of amino acid (15/60) involved
proline. Proline has been well known to affect the confor-
mation of the polypeptide (34). 
One of the mutants identified in this study carried a single
nucleotide substitution at codon 57 (CAC→GAC) result-
ing in an amino acid substitution (His→Asp) (Table 1).
This is a unique mutation specific to M. bovis, which is nat-
urally resistant to PZA (16). This difference has been used
to discriminate M. tuberculosis from M. bovis (35, 36). Since
others have also reported PZA-resistant M. tuberculosis
mutants carrying the same mutation (23), special caution
should be taken in the discrimination of the two organisms
using only the polymorphism at codon 57 of the pncA gene.
Instead of using it alone, several other polymorphisms in
other genes, such as oxyR, unique to either M. tuberculosis or
M. bovis, should be tested simultaneously (35).
Lastly, the mutations were dispersed throughout the pncA
gene including the upstream region (Fig. 1). This scattered
pattern of mutation is more obvious when all reported data
are combined (Fig. 1B). To date, mutations have been found
to alter 44% of the codons (81/186 codons) with no specific
hot spots of variation. It should be noted that the high fre-
quencies of mutation at some codons (e.g., codons 140 and
149) were the result of the spread of single mutant strain
during any outbreak (17). This is very unusual compared to
other drug-related genes, such as rpoB and katG, where sev-
eral restricted sites are involved in the conversion to drug
resistance (31, 38). This implies that the whole region encom-
passing the pncA may be a hot spot of mutation in the ge-
nome. 
The most frequent mutation in this study (6/92, 6.5%)
involved nucleotide -11, 5′ -of the coding region, with a sin-
gle nucleotide substitution (A→G). The same mutant was
also identified in other studies (2, 17, 21, 23) with the high-
est frequency of this mutation reported in Russia (5/31, 16%)
(20). It is well known that this region upstream of the start
codon (AUG) of each mRNA is a critical site for the correct
positioning of the ribosome in the initiation of protein syn-
thesis (39). Thus, this substitution may prevent appropriate
binding of the ribosome to the pncA mRNA leading to a
failure in PZase protein synthesis. This hypothesis must be
confirmed by further study. 
Conclusively, this study confirmed the usefulness of DNA-
based detection of PZA-resistant M. tuberculosis. Consider-
ing the dispersed and diverse mutational characteristics of
the pncA gene, an automated DNA sequencing approach
appears to be the best strategy for rapid detection of PZA-
resistant M. tuberculosis. In addition, the high diversity of
the pncA mutations will be epidemiologically useful in trac-
ing the outbreak or transmission of PZA-resistant M. tuber-
culosis strains (17, 40, 41). 
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